UA28031C2 - Medicinal form of derivatives 5-nitroimidasole, pharmaceutical composition for gastrointestinal tract parasitic and infectious deseases treatment. gastroprotected microgranules of derivatives 5-nitroimidasole, microgranules of derivatives 5-nitroimidasole with a prolonged release of a medicinal agent. - Google Patents

Medicinal form of derivatives 5-nitroimidasole, pharmaceutical composition for gastrointestinal tract parasitic and infectious deseases treatment. gastroprotected microgranules of derivatives 5-nitroimidasole, microgranules of derivatives 5-nitroimidasole with a prolonged release of a medicinal agent.

Info

Publication number
UA28031C2
UA28031C2 UA96083232A UA96083232A UA28031C2 UA 28031 C2 UA28031 C2 UA 28031C2 UA 96083232 A UA96083232 A UA 96083232A UA 96083232 A UA96083232 A UA 96083232A UA 28031 C2 UA28031 C2 UA 28031C2
Authority
UA
Ukraine
Prior art keywords
nitroimidasole
derivatives
microgranules
medicinal
gastrointestinal tract
Prior art date
Application number
UA96083232A
Other languages
Russian (ru)
Ukrainian (uk)
Inventor
Жерар Ледюк
Патріс Дебрежеа
Патрис Дебрежеа
Original Assignee
Лаборатуар Де Продюі Етік Етіфарм
Лаборатуар Де Продюи Етик Етифарм
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9400394A external-priority patent/FR2715067B1/en
Application filed by Лаборатуар Де Продюі Етік Етіфарм, Лаборатуар Де Продюи Етик Етифарм filed Critical Лаборатуар Де Продюі Етік Етіфарм
Publication of UA28031C2 publication Critical patent/UA28031C2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Medicinal form contains a combination of microgranules of derivatives 5-nitroimidasole, consisting, on the one hand, of gastro-resistant microgranules and, on the other hand, of microgranules with a prolonged release of a medicinal agent. Gastroresistant microgranules are intended to guarantee the efficiency of the medicinal form of the present invention, primarily, in the upper part of gastrointestinal tract, while the microgranules with a prolonged medicinal agent release are operate mainly in the lower part of gastrointestinal tract.
UA96083232A 1994-01-14 1995-01-12 Medicinal form of derivatives 5-nitroimidasole, pharmaceutical composition for gastrointestinal tract parasitic and infectious deseases treatment. gastroprotected microgranules of derivatives 5-nitroimidasole, microgranules of derivatives 5-nitroimidasole with a prolonged release of a medicinal agent. UA28031C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9400394A FR2715067B1 (en) 1994-01-14 1994-01-14 New dosage form of 5-nitro-imidazole derivatives effective for the treatment of parasitic infections and infections of the entire gastrointestinal tract.
PCT/FR1995/000039 WO1995019168A1 (en) 1994-01-14 1995-01-12 Microgranules of 5-nitro imidazole derivatives

Publications (1)

Publication Number Publication Date
UA28031C2 true UA28031C2 (en) 2000-10-16

Family

ID=9459066

Family Applications (1)

Application Number Title Priority Date Filing Date
UA96083232A UA28031C2 (en) 1994-01-14 1995-01-12 Medicinal form of derivatives 5-nitroimidasole, pharmaceutical composition for gastrointestinal tract parasitic and infectious deseases treatment. gastroprotected microgranules of derivatives 5-nitroimidasole, microgranules of derivatives 5-nitroimidasole with a prolonged release of a medicinal agent.

Country Status (19)

Country Link
JP (1) JPH09507499A (en)
KR (1) KR100320140B1 (en)
CN (1) CN1088357C (en)
AT (1) ATE187068T1 (en)
AU (1) AU705570B2 (en)
BR (1) BR9506507A (en)
CZ (1) CZ286080B6 (en)
DE (1) DE69513632T2 (en)
DK (1) DK0739201T3 (en)
ES (1) ES2139883T3 (en)
MA (1) MA23429A1 (en)
MX (1) MX9602772A (en)
NZ (1) NZ279238A (en)
OA (1) OA10583A (en)
PL (1) PL178424B1 (en)
PT (1) PT739201E (en)
RU (1) RU2152212C1 (en)
SK (1) SK282066B6 (en)
UA (1) UA28031C2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4331930B2 (en) * 2001-10-17 2009-09-16 武田薬品工業株式会社 High content granules of acid labile drugs
KR20190026962A (en) 2014-09-05 2019-03-13 심바이오믹스 세러퓨틱스 엘엘씨 Secnidazole for use in the treatment of bacterial vaginosis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5256684A (en) * 1985-06-13 1993-10-26 The Procter & Gamble Company Methods and compositions for the treatment of gastrointestinal disorders
DE3822095A1 (en) * 1988-06-30 1990-01-04 Klinge Co Chem Pharm Fab NEW MEDICAMENT FORMULATION AND METHOD FOR THE PRODUCTION THEREOF
WO1991017744A1 (en) * 1990-05-14 1991-11-28 Jernberg Gary R Surgical implant and method incorporating chemotherapeutic agents

Also Published As

Publication number Publication date
PL315530A1 (en) 1996-11-12
SK282066B6 (en) 2001-10-08
JPH09507499A (en) 1997-07-29
AU1580395A (en) 1995-08-01
DE69513632T2 (en) 2000-04-06
ES2139883T3 (en) 2000-02-16
OA10583A (en) 2002-07-10
AU705570B2 (en) 1999-05-27
DE69513632D1 (en) 2000-01-05
CZ286080B6 (en) 2000-01-12
RU2152212C1 (en) 2000-07-10
CN1088357C (en) 2002-07-31
SK91496A3 (en) 1996-12-04
CN1138826A (en) 1996-12-25
ATE187068T1 (en) 1999-12-15
BR9506507A (en) 1997-09-09
MX9602772A (en) 1997-05-31
KR100320140B1 (en) 2002-07-02
CZ205596A3 (en) 1996-10-16
PL178424B1 (en) 2000-04-28
DK0739201T3 (en) 2000-05-01
MA23429A1 (en) 1995-10-01
PT739201E (en) 2000-05-31
NZ279238A (en) 1998-03-25

Similar Documents

Publication Publication Date Title
MY129356A (en) Electrospun pharmaceutical compositions
TW355683B (en) Composition containing micronized nebivolol
WO2000030622A3 (en) Utilisation of dialkylfumarates for treating host-versus-graft reactions and auto-immune diseases
MY124695A (en) Novel composition and use.
AU2002231691A1 (en) Novel medicament compositions based on anticholinesterase drugs and on ciclesonides
MY127980A (en) A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders
HK1048986A1 (en) 2'-Substituted 1,1'-iphenyl-2-carbonamides, methodfor the production thereof, use thereof as medicament and pharmaceutical preparations containing said compounds.
AU9018898A (en) Phosphazole-containing nucleoside analogs, related compounds, pharmaceutical compositions thereof, and their use in in vitro medicinal treatments
HK1045113A1 (en) Oral administration form for administering a fixed tramadol and diclofenac combination
CA2294921A1 (en) Levobupivacaine and its use
IL155097A0 (en) Methods, compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue
ZA200308221B (en) Pharmaceutical compositions for oral and topical administration.
GB0204331D0 (en) Hyaluronan as a cytotoxic agent, drug pre-sensitizer and chemo-sensitizer in the treatment of disease
CA2350659A1 (en) Pharmaceutical composition for modified release insulin sensitiser
EP1304108A3 (en) Anti-arrhythmic composition and methods of treatment
UA28031C2 (en) Medicinal form of derivatives 5-nitroimidasole, pharmaceutical composition for gastrointestinal tract parasitic and infectious deseases treatment. gastroprotected microgranules of derivatives 5-nitroimidasole, microgranules of derivatives 5-nitroimidasole with a prolonged release of a medicinal agent.
HK1075654A1 (en) Hyperforin derivatives, the use thereof and formulations containing them
NZ501832A (en) Angiotensin-peptide carrier conjugates for treating diseases associated with the renin-angiotensin system
HUP0200529A2 (en) Optically pure camptothecin analogues, pharmaceutical compositions containing them and their use
WO2002041841A3 (en) Compositions for adhesion prevention
EP1221945A4 (en) Methods, pharmaceutical and therapeutic compositions for administering adenosine
BG104692A (en) Extended release tiagabine formulation
WO1998036778A8 (en) Sustained drug delivery and compositions useful therefor
AU1399100A (en) Therapeutic treatment with immunogenic drugs
EP2305267A3 (en) Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive